Waverly Advisors LLC Acquires 1,853 Shares of Medpace Holdings, Inc. $MEDP

Waverly Advisors LLC increased its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 89.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,931 shares of the company’s stock after buying an additional 1,853 shares during the period. Waverly Advisors LLC’s holdings in Medpace were worth $1,888,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Geneos Wealth Management Inc. increased its position in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after acquiring an additional 37 shares in the last quarter. Steigerwald Gordon & Koch Inc. acquired a new position in shares of Medpace during the fourth quarter worth approximately $30,000. Elyxium Wealth LLC bought a new stake in shares of Medpace during the fourth quarter valued at approximately $30,000. Quarry LP bought a new stake in shares of Medpace during the third quarter valued at approximately $35,000. Finally, Bayban acquired a new stake in shares of Medpace in the fourth quarter valued at approximately $44,000. Institutional investors own 77.98% of the company’s stock.

Wall Street Analysts Forecast Growth

MEDP has been the topic of several research reports. Jefferies Financial Group downgraded Medpace from a “buy” rating to a “hold” rating and upped their price objective for the stock from $490.00 to $515.00 in a report on Tuesday, July 7th. Weiss Ratings reissued a “hold (c+)” rating on shares of Medpace in a research note on Thursday, July 2nd. Robert W. Baird boosted their target price on Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a research report on Friday, July 24th. Truist Financial upped their price target on Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a research note on Friday, July 24th. Finally, Royal Bank Of Canada raised their price target on Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a report on Friday, July 24th. Two equities research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $584.18.

Medpace Trading Down 1.1%

NASDAQ:MEDP opened at $578.30 on Friday. Medpace Holdings, Inc. has a 1 year low of $373.00 and a 1 year high of $677.90. The stock has a 50-day moving average price of $504.72 and a two-hundred day moving average price of $493.19. The stock has a market cap of $16.14 billion, a price-to-earnings ratio of 33.90, a PEG ratio of 2.61 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. During the same quarter last year, the firm posted $3.10 earnings per share. Medpace’s revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Sell-side analysts forecast that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Insiders Place Their Bets

In other news, General Counsel Stephen P. Ewald sold 16,349 shares of the company’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the completion of the transaction, the general counsel owned 20,343 shares in the company, valued at $9,154,350. This represents a 44.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO August J. Troendle sold 3,510 shares of the stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $600.01, for a total transaction of $2,106,035.10. Following the sale, the chief executive officer directly owned 638,946 shares of the company’s stock, valued at $383,373,989.46. This represents a 0.55% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 31,087 shares of company stock worth $16,203,054. Company insiders own 20.50% of the company’s stock.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.